Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy

BMC Gastroenterology

Volumn 10, Issue , 2010, Pages

  Huo, Teh I ^a,b   Hsu, Chia Y ^a,b   Huang, Yi H ^a,b   Su, Chien W ^a,b   Lin, Han C ^a,b   Lee, Rheun C ^a,b   Chiou, Yi Y ^a,b   Chiang, Jen H ^a,b   Lee, Pui C ^b   Lee, Shou D ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ALANINE AMINOTRANSFERASE; ALCOHOL; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE;

ACCURACY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER INVASION; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; FEASIBILITY STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RADIOFREQUENCY ABLATION; TREATMENT PLANNING; TUMOR VOLUME; CATHETER ABLATION; KARNOFSKY PERFORMANCE STATUS; LIVER TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; NONPARAMETRIC TEST; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; SURVIVAL;

ACETIC ACID; ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; ETHANOL; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TUMOR BURDEN;

EID: 78650640689     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-10-146     Document Type: Article

References (40)

1. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003, 139:817-23.
2. Pocobelli G, Cook LS, Brant R, Lee SS. Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis. Liver Int 2008, 28:1272-9. 10.1111/j.1478-3231.2008.01704.x, 18384523.
3. Pompili M, Rapaccini GL, de Luca F, Caturelli E, Astone A, Siena DA, Villani MR, Grattagliano A, Cedrone A, Gasbarrini G. Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection. Cancer 1997, 79:1501-8. 10.1002/(SICI)1097-0142(19970415)79:8<1501::AID-CNCR9>3.0.CO;2-D, 9118030.
4. Trevisani F, Magini G, Santi V, Morselli-Labate AM, Cantarini MC, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Farinati F, Zoli M, Borzio F, Giannini EG, Caturelli E, Bernardi M. Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am J Gastroenterol 2007, 102:1022-31. 10.1111/j.1572-0241.2007.01100.x, 17313497.
5. Chen WT, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, Wu CW. Recurrent hepatocellular carcinoma after hepatic resection: prognostic factors and long-term outcome. Eur J Surg Oncol 2004, 30:414-20. 10.1016/j.ejso.2004.01.013, 15063895.
6. Martins A, Cortez-Pinto H, Marques-Vidal P, Mendes N, Silva S, Fatela N, Glória H, Marinho R, Távora I, Ramalho F, de Moura MC. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int 2006, 26:680-7. 10.1111/j.1478-3231.2006.001285.x, 16842324.
7. The Cancer of the Liver Italian Program (CLIP) investigators Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000, 31:840-5. 10.1053/he.2000.5628, 10733537, The Cancer of the Liver Italian Program (CLIP) investigators.
8. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-9. 10.1056/NEJM199603143341104, 8594428.
9. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009, 24:346-53. 10.1111/j.1440-1746.2009.05784.x, 19220670.
10. Kulik LM, Mulcahy MF, Omary RA, Salem R. Emerging approaches in hepatocellular carcinoma. J Clin Gastroenterol 2007, 41:839-54. 10.1097/MCG.0b013e318060ac52, 17881931.
11. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 2004, 127:1714-23. 10.1053/j.gastro.2004.09.003, 15578509.
12. Huang GT, Lee PH, Tsang YM, Lai MY, Yang PM, Hu RH, Chen PJ, Kao JH, Sheu JC, Lee CZ, Chen DS. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg 2005, 242:36-42. 10.1097/01.sla.0000167925.90380.fe, 1357702, 15973099.
13. Ercolani G, Grazi GL, Ravaioli M, Cescon M, Gardini A, Varotti G, Del Gaudio M, Nardo B, Cavallari A. Liver resection for multiple colorectal metastases: influence of parenchymal involvement and total tumor volume, vs number or location, on long-term survival. Arch Surg 2002, 137:1187-92. 10.1001/archsurg.137.10.1187, 12361432.
14. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009, 49:832-8. 10.1002/hep.22693, 19152426.
15. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-36. 10.1002/hep.20933, 16250051.
16. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. Clinical management of hepatocellular carcinoma: Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001, 35:421-30. 10.1016/S0168-8278(01)00130-1, 11592607.
17. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003, 124:91-6. 10.1053/gast.2003.50016, 12512033.
18. Huo TI, Lin HC, Hsia CY, Wu JC, Lee PC, Chi CW, Lee SD. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol 2007, 102:1920-30. 10.1111/j.1572-0241.2007.01370.x, 17573792.
19. Huo TI, Lee SD, Lin HC. Selecting an optimal prognostic system for liver cirrhosis: the model for end-stage liver disease and beyond. Liver Int 2008, 28:606-13. 10.1111/j.1478-3231.2008.01727.x, 18433390.
20. Huo TI, Lin HC, Wu JC, Lee FY, Hou MC, Lee PC, Chang FY, Lee SD. Proposal of a modified Child-Turcotte-Pugh scoring system and comparison with the model for end-stage liver disease for outcome prediction in patients with cirrhosis. Liver Transpl 2006, 12:65-71. 10.1002/lt.20560, 16382473.
21. Huo TI, Lee PC, Huang YH, Wu JC, Lin HC, Chiang JH, Lee SD. The sequential changes of the model for end-stage liver disease score correlate with the severity of liver cirrhosis in patients with hepatocellular carcinoma undergoing locoregional therapy. J Clin Gastroenterol 2006, 40:543-50. 10.1097/00004836-200607000-00014, 16825938.
22. Huo TI, Huang YH, Lin HC, Wu JC, Chiang JH, Lee PC, Chang FY, Lee SD. Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol 2006, 101:975-82. 10.1111/j.1572-0241.2006.00462.x, 16573785.
23. Huo TI, Huang YH, Wu JC, Lee PC, Chang FY, Lee SD. Induction of complete tumor necrosis may reduce intrahepatic metastasis and prolong survival in patients with hepatocellular carcinoma undergoing locoregional therapy: a prospective study. Ann Oncol 2004, 15:775-80. 10.1093/annonc/mdh184, 15111346.
24. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med 1997, 16:965-80. 10.1002/(SICI)1097-0258(19970515)16:9<965::AID-SIM509>3.0.CO;2-O, 9160492.
25. Feinsten AR. Clinical biostatistics XVI. The process of prognostic stratification. Clin Pharmacol Ther 1972, 13:609-24.
26. Foster MR. Key concepts in model selection: Performance and generalizability. J Math Psychol 2000, 44:205-31. 10.1006/jmps.1999.1284, 10733865.
27. Yeh CN, Chen MF, Lee WC, Jeng LB. Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: univariate and multivariate analysis. J Surg Oncol 2002, 81:195-202. 10.1002/jso.10178, 12451624.
28. Yao F, Ferrell L, Bass N, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinomas: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33:1394-1403. 10.1053/jhep.2001.24563, 11391528.
29. Decaens T, Roudot-Thoraval F, Hadni-Bresson S, Meyer C, Gugenheim J, Durand F, Bernard PH, Boillot O, Sulpice L, Calmus Y, Hardwigsen J, Ducerf C, Pageaux GP, Dharancy S, Chazouilleres O, Cherqui D, Duvoux C. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 2006, 12:1761-9. 10.1002/lt.20884, 16964590.
30. Cho YK, Chung JW, Kim JK, Ahn YS, Kim MY, Park YO, Kim WT, Byun JH. Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer 2008, 112:352-61. 10.1002/cncr.23185, 18008352.
31. Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Lee PC, Loong CC, Chiang JH, Huo TI, Lee SD. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer 2010, 116:3006-14. 10.1002/cncr.25044, 20564406.
32. Hosaka T, Ikeda K, Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Saitoh S, Arase Y, Kumada H. Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma. Liver Int 2009, 29:736-42. 10.1111/j.1478-3231.2008.01901.x, 19018978.
33. Bouza C, López-Cuadrado T, Alcázar R, Saz-Parkinson Z, Amate JM. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol 2009, 9:31. 10.1186/1471-230X-9-31, 19432967.
34. Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, Loong CC, Chiou YY, Chiang JH, Lee PC, Huo TI, Lee SD. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol 2010, 53:108-17. 10.1016/j.jhep.2010.01.038, 20451283.
35. Pompili M, Rapaccini GL, Covino M, Pignataro G, Caturelli E, Siena DA, Villani MR, Cedrone A, Gasbarrini G. Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. Cancer 2001, 92:126-35. 10.1002/1097-0142(20010701)92:1<126::AID-CNCR1300>3.0.CO;2-V, 11443618.
36. Huo TI, Huang YH, Wu JC. Percutaneous ablation therapy for hepatocellular carcinoma: current practice and future perspectives. J Chin Med Assoc 2005, 68:155-9. 10.1016/S1726-4901(09)70239-4, 15850062.
37. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009, 29:502-10. 10.1111/j.1478-3231.2008.01957.x, 2711257, 19141028.
38. Kirikoshi H, Saito S, Yoneda M, Fujita K, Mawatari H, Uchiyama T, Higurashi T, Imajo K, Sakaguchi T, Atsukawa K, Sawabe A, Kanesaki A, Takahashi H, Abe Y, Inamori M, Kobayashi N, Kubota K, Ueno N, Nakajima A. Outcomes and factors influencing survival in cirrhotic cases with spontaneous rupture of hepatocellular carcinoma: a multicenter study. BMC Gastroenterol 2009, 9:29. 10.1186/1471-230X-9-29, 2685387, 19405938.
39. Wu JC, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, Huo TI, Sheen IJ, Lee SD, Lui WY. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009, 51:890-7. 10.1016/j.jhep.2009.07.009, 19747749.
40. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:698-711. 10.1093/jnci/djn134, 18477802.